Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider trading activity and does not contain financial performance data.
Material Changes
The only material change disclosed is a transaction by Sir Robert Wilson, a Director. On July 31, 2007, he purchased 5,000 Ordinary shares of GlaxoSmithKline plc at a price of GBP 12.53 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share purchase in accordance with Disclosure and Transparency Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Type: Purchase of Ordinary Shares.
- Insider: Sir Robert Wilson (Director).
- Date: July 31, 2007.
- Volume: 5,000 shares.
- Price: GBP 12.53 per share.
- Regulatory Basis: Notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(b).